Reirradiation With Concurrent Paclitaxel for Breast Cancer

Breast Cancer Clinical Trial

Official title:

A Phase I Study of Twice Weekly Paclitaxel and Radical Re-irradiation Using Helical Tomotherapy for Aggressive Chest Wall Recurrences of Breast Cancer

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02058667
• Other study ID #: 13-BRE-47-MCC
• Status: Withdrawn
• Phase: Phase 1
• First received: January 31, 2014
• Last updated: November 11, 2016
• Start date: July 2014

Study information

• Verified date: November 2016
• Source: University of Kentucky
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationUnited States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this trial in addition to a dose finding study for concurrent Paclitaxel, will be to establish a treatment algorithm for chest wall reirradiation. A nominal margin of at least 5cm will be used on the protocol and extending it to 7cm. Considering the standard treatment of breast cancer incorporates a cumulative dose of 60Gy, delivering an additional 50.4 Gy followed by a boost should target a total dose of 120 Gy.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. primary completion date: December 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Pathologically proven diagnosis of breast cancer with clinical evidence of recurrent disease on the chest wall following treatment that included radiotherapy, and for which there is no current standard of care or curative resection able to be performed

• Patients are permitted to have received prior therapy, but must have received a minimum of 30 Gy to the chest wall with a minimal interval since completion of radiation therapy equal to or greater than 6 months.

• Patients are permitted to have been treated with previous systemic chemotherapy. A minimal time interval since last dose of cytotoxic chemotherapy must be equal to or greater than 21 days, and all acute toxicities should be resolved to less than grade 2, and hematologic counts should meet study criteria. With regards to toxicity, patients who have left sided chest wall recurrences should not have previously exceeded more than 450 mg/m2 doxorubicin due to expected cumulative cardiotoxicity. Prior taxane therapy is allowed, however, there should be no reported anaphylactic reactions of grade 3 or higher.

• Age =18 years

• ECOG performance status =2

• Life expectancy of greater than 3 months

• Normal organ and marrow function as defined below:

• absolute neutrophil count =1,500/mcL

• platelets =100,000/mcL

• total bilirubin < 1.5 x institutional upper limit of normal

• AST(SGOT)/ALT(SGPT) =2.5 × institutional upper limit of normal

• creatinine within normal institutional limits OR creatinine clearance =60 mL/min/1.73 m2 for patients with creatinine

• levels above institutional normal

• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

• Patients who have had radiotherapy within 6 months prior to entering the study or those who have not recovered to < grade 2 adverse events due to radiation

• Patients who have experienced a previous grade 3 or 4 anaphylactic reaction to Paclitaxel.

• Patients with grade > 2 neuropathy attributable to previous administration of Taxane chemotherapy.

• Patients who have received prior chemotherapy are allowed, provided they have been off systemic therapy for 21 days and all acute toxicities have resolved to less than grade 2. Patients who have received Paclitaxel within 3 months of study entry and have developed documented progressive disease despite therapy.

• Patients who are receiving any other investigational agents

• Patients with known brain metastases should have their brain metastases treated prior to enrollment on this protocol. Subjects may enroll on this trial after completion of whole brain radiation therapy and/or Stereotactic Radiosurgery, provided they are clinically without evidence of progressive brain metastases.

• Patient who are actively receiving other cytotoxic or antibiologic chemotherapies. For patients with Her-2/neu positive disease, Trastuzumab (Herceptin) is NOT ALLOWED on this study, and should be withheld during the 8 weeks of therapy, and can be resumed no sooner than 14 days following completion of protocol therapy

• Women with a confirmed intrauterine pregnancy

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

• Pregnant women are excluded from this study because Paclitaxel is an antimicrotubule agent with known potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with Paclitaxel, breastfeeding should be discontinued if the mother is treated with Paclitaxel

• HIV-positive patients on combination antiretroviral therapy are ineligible.

• Patients with poor cardiac function defined as an ejection fraction (EF) < 40% are excluded.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Radiation:
• Paclitaxel+Initial Radiation+Boost
Paclitaxel twice weekly + Initial Fields Radiation + Boost Radiation (10Gy)

Locations

Country	Name	City	State
United States	Markey Cancer Center	Lexington	Kentucky

Sponsors (1)

Lead Sponsor	Collaborator
University of Kentucky

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MTD identification	To identify the maximum tolerated dose of twice weekly Paclitaxel given concurrently with chest wall re-irradiation using helical tomotherapy for aggressive breast cancer recurrences	From first dose at week 1 until unacceptable toxicity occurs, up to 7 weeks	Yes
Secondary	Time to progression		Up to 6 months	Yes
Secondary	Local Control Rate of Dermal Disease at 6 months		6 months	No
Secondary	Rate of study-defined grade 1-2 toxicities, and all grade 3 or higher toxicities		Up to 6 months	Yes
Secondary	Her-2/neu transformation	Her-2/neu transformation from initial therapy to the time of development of dermal metastasis or recurrence	1-6 months	No